Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 5/20 | 0.57 |
| ▸ | DRD2 | P14416 | 5/20 | 0.57 |
| ▸ | ABCB1 | P08183 | 11/20 | 0.53 |
| ▸ | DHFR | P00374 | 2/20 | 0.51 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.46 |
| ▸ | MPO | P05164 | 1/20 | 0.45 |
| ▸ | LTA4H | P09960 | 1/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4011604 | 0.81 | HSD17B10 (0.52) | ABCB1DHFR | |
| SCHEMBL3947733 | 0.78 | COMT (0.49) | — | |
| SCHEMBL4183309 | 0.75 | HTR1A (1.00) | HTR1ADRD2ABCB1ABCG2 | |
| SCHEMBL23854651 | 0.74 | TSHR (0.50) | DHFRMPO | |
| Hydrochloric Acid SCHEMBL29155672 | 0.73 | TSHR (0.48) | DHFRMPO | |
| SCHEMBL4014567 | 0.72 | MPO (0.48) | MPOLTA4HMAPK14 | |
| SCHEMBL1412912 | 0.72 | HTR1A (0.73) | HTR1ADRD2ABCB1LTA4H | |
| SCHEMBL17197391 | 0.71 | HTR1A (0.79) | HTR1ADRD2ABCB1ABCG2 | |
| SCHEMBL9065299 | 0.71 | HTR1A (0.72) | HTR1ADRD2ABCB1DHFRABCG2 | |
| SCHEMBL3499891 | 0.70 | HPGD (0.59) | DRD2MPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2044063-A1 | PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | Astra Zeneca AB (SE) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008001070-A1 | PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2008-01-03 | — | — | WO | disclosed |
| US-20080004302-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004302-A1 | Novel Compounds | CYP11B2, CYP11B1, CYP46A1 | HTR1A 1963/4885DRD2 4059/4885ABCB1 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.